Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate cancer: advances in immunotherapy.
Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Hurwitz AA, et al. Among authors: kwon ed. BioDrugs. 2003;17(2):131-8. doi: 10.2165/00063030-200317020-00005. BioDrugs. 2003. PMID: 12641491 Review.
Augmentation of T cell levels and responses induced by androgen deprivation.
Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Roden AC, et al. Among authors: kwon ed. J Immunol. 2004 Nov 15;173(10):6098-108. doi: 10.4049/jimmunol.173.10.6098. J Immunol. 2004. PMID: 15528346
Immunotherapy for prostate cancer.
Karnes RJ, Whelan CM, Kwon ED. Karnes RJ, et al. Among authors: kwon ed. Curr Pharm Des. 2006;12(7):807-17. doi: 10.2174/138161206776056001. Curr Pharm Des. 2006. PMID: 16515497 Review.
Immunotherapy in prostate cancer.
Sobol I, Thompson RH, Dong H, Krco C, Kwon ED. Sobol I, et al. Among authors: kwon ed. Curr Urol Rep. 2015 Jun;16(6):34. doi: 10.1007/s11934-015-0509-7. Curr Urol Rep. 2015. PMID: 25894495 Review.
Immunotherapy for urological malignancies.
Krejci KG, Markiewicz MA, Kwon ED. Krejci KG, et al. Among authors: kwon ed. J Urol. 2004 Feb;171(2 Pt 1):870-6. doi: 10.1097/01.ju.0000101161.17279.09. J Urol. 2004. PMID: 14713844 Review.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators. Kwon ED, et al. Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24831977 Free PMC article. Clinical Trial.
161 results